{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:11:55Z","timestamp":1783696315199,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrent stroke burden exceeds 10% within the first year. Dual antiplatelet therapy (DAPT) is recommended for short-term secondary prevention after non-cardioembolic high-risk TIA or ischemic stroke (nc-IS), yet uncertainty persists regarding its true efficacy, optimal timing, duration, regimen, and bleeding risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of DAPT vs. single antiplatelet therapy (SAPT) after TIA or nc-IS and to identify clinical and study-level effect modifiers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, and Scopus were searched through October 13, 2025, for randomized trials (RTs) and cohort studies comparing DAPT and SAPT in adults (\u226518\u202fyears) with TIA or nc-IS. The review was registered in PROSPERO (CRD420251017979). Recurrent stroke and major bleeding were the primary efficacy and safety outcomes of interest, respectively. Eligible studies included those comparing any DAPT vs. SAPT regimen reporting recurrent ischemic stroke or major bleeding. Two reviewers independently screened studies using predefined criteria and resolved discrepancies by consensus. Data were extracted independently by two reviewers following PRISMA guidelines. Study quality was assessed using the Cochrane RoB 2 and Newcastle\u2013Ottawa tools. Pooled risk ratios (pRRs; 95% CIs) were calculated using random-effects models. Subgroup and meta-regression analyses explored treatment modifiers, and certainty of evidence was graded using GRADE. Data were analyzed using Stata version 18.5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-seven studies (18 RTs and 9 observational; 123,136 participants) were included. DAPT was associated with significant reduction in stroke recurrence compared with SAPT (pRR 0.83; 95% CI 0.78\u20130.88; I\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f57%). Benefit was greatest when DAPT was initiated \u226424\u202fh-7\u202fdays and continued short-term (\u226490\u202fdays), particularly when initiated with a loading dose. Efficacy was consistent across age, sex, stroke severity (including NIHSS &amp;gt;3\u2013\u226415), study design, and geographic setting, and extended to other DAPT regimens beyond aspirin-clopidogrel combinations. Major bleeding occurred more often with DAPT (pRR 1.29; 95% CI 1.00\u20131.66; I\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f60%). Bleeding risk appeared slightly higher with aspirin-clopidogrel regimens and among women but was otherwise consistent across subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early, time-limited DAPT with a loading dose was associated with lower stroke recurrence and modest bleeding risk, with benefits extending to mild-to-moderate strokes and alternative combinations beyond the standard aspirin\u2013clopidogrel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:uri>\n                      , identifier CRD420251017979.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1750241","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T17:44:07Z","timestamp":1768239847000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual antiplatelet therapy use after non-cardioembolic ischemic stroke or transient ischemic attack: a meta-analysis of trials and cohort studies"],"prefix":"10.3389","volume":"16","author":[{"given":"Admire","family":"Hlupeni","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, St Luke\u2019s Hospital","place":["Chesterfield, MO, United States"]},{"name":"Midlands State University","place":["Gweru, Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Arooj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St Luke\u2019s Hospital","place":["Chesterfield, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebisi","family":"Adejola","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St Luke\u2019s Hospital","place":["Chesterfield, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pohlman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St Luke\u2019s Hospital","place":["Chesterfield, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Donepudi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St Luke\u2019s Hospital","place":["Chesterfield, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2010.11.006","article-title":"2011 ASA\/ACCF\/AHA\/AANN\/AANS\/ACR\/ASNR\/CNS\/SAIP\/SCAI\/SIR\/SNIS\/SVM\/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease","volume":"57","author":"Brott","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/17474930251340799","article-title":"Recurrent ischemic stroke in young adults: a multicenter cohort study, systematic review, and meta-analysis","author":"Kwok","year":"2025","journal-title":"Int J Stroke"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1161\/STROKEAHA.121.035555","article-title":"Ischemic benefit and hemorrhage risk of Ticagrelor-aspirin versus aspirin in patients with acute ischemic stroke or transient ischemic attack","volume":"52","author":"Johnston","year":"2021","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Or","year":"2012","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus Clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"E364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejim.2022.03.017","article-title":"P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: a systematic review and meta-analysis","volume":"100","author":"Pomero","year":"2022","journal-title":"Eur J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"E217","DOI":"10.1161\/STROKEAHA.120.033033","article-title":"Dual antiplatelet therapy versus aspirin in patients with stroke or transient ischemic attack: meta-analysis of randomized controlled trials","volume":"52","author":"Bhatia","year":"2021","journal-title":"Stroke"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.K5108","article-title":"Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis","volume":"363","author":"Hao","year":"2018","journal-title":"BMJ"},{"key":"ref12","year":""},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/STROKEAHA.115.012293","article-title":"Recurrent ischemic lesions after acute Atherothrombotic stroke: Clopidogrel plus aspirin versus aspirin alone","volume":"47","author":"Hong","year":"2016","journal-title":"Stroke"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","article-title":"Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial","volume":"111","author":"Markus","year":"2005","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40265-024-02034-3","article-title":"Sex-based outcomes of dual-antiplatelet therapy after percutaneous coronary intervention: a pairwise and network meta-analysis","volume":"84","author":"Agbaedeng","year":"2024","journal-title":"Drugs"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1161\/ATVBAHA.122.318725","article-title":"Sex differences in outcomes of Ticagrelor therapy with or without aspirin after percutaneous coronary intervention in patients with acute coronary syndrome: a post hoc secondary analysis of the TICO randomized clinical trial","volume":"43","author":"Lee","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1001\/jamacardio.2021.1720","article-title":"Sex differences among patients with high risk receiving Ticagrelor with or without aspirin after percutaneous coronary intervention: a subgroup analysis of the TWILIGHT randomized clinical trial","volume":"6","author":"Vogel","year":"2021","journal-title":"JAMA Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1161\/01.str.16.3.406","article-title":"Persantine aspirin trial in cerebral ischemia part II: endpoint results. The American-Canadian Co-Operative Study group","volume":"16","year":"1985","journal-title":"Stroke"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1600-0404.1987.tb03596.x","article-title":"Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks","volume":"76","author":"Matias-Guiu","year":"1987","journal-title":"Acta Neurol Scand"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","article-title":"Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial","volume":"6","author":"Kennedy","year":"2007","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1159\/000327035","article-title":"The Japanese Aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial","volume":"31","author":"Uchiyama","year":"2011","journal-title":"Cerebrovasc Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2011.09.038","article-title":"Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study","volume":"313","author":"Nakamura","year":"2012","journal-title":"J Neurol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jocn.2014.05.038","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke","volume":"22","author":"He","year":"2015","journal-title":"J Clin Neurosci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.114.014791","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial one-year outcomes","volume":"132","author":"Wang","year":"2015","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/S12883-015-0480-4","article-title":"Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study","volume":"15","author":"Christiansen","year":"2015","journal-title":"BMC Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012652","article-title":"Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset","volume":"8","author":"Aoki","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40169-019-0223-z","article-title":"Comparison of administration of clopidogrel with aspirin versus aspirin alone in prevention of secondary stroke after transient ischemic attack","volume":"8","author":"Khazaei","year":"2019","journal-title":"Clin Transl Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1161\/STROKEAHA.118.022691","article-title":"Comparative effectiveness of aspirin and Clopidogrel versus aspirin in acute minor stroke or transient ischemic attack","volume":"50","author":"Kim","year":"2019","journal-title":"Stroke"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"E006474","DOI":"10.1161\/CIRCOUTCOMES.119.006474","article-title":"Comparative effectiveness of dual antiplatelet therapy with aspirin and clopidogrel versus aspirin monotherapy in mild-to-moderate acute ischemic stroke according to the risk of recurrent stroke: an analysis of 15 000 patients from a nationwide, multicenter registry","volume":"13","author":"Lee","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/acn3.51541","article-title":"Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization","volume":"9","author":"Fan","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2309137","article-title":"Dual antiplatelet treatment up to 72 hours after ischemic stroke","volume":"389","author":"Gao","year":"2023","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"220","DOI":"10.17712\/nsj.2023.4.20230021","article-title":"Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke","volume":"28","author":"Algarni","year":"2023","journal-title":"Neurosciences (Riyadh)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1159\/000535171","article-title":"Treatment strategies and prognosis for moderate stroke patients in China","volume":"53","author":"Wang","year":"2023","journal-title":"Cerebrovasc Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2023.100171","article-title":"Safety and efficacy of short-term dual antiplatelet therapy combined with intensive rosuvastatin in acute ischemic stroke","volume":"78","author":"Deng","year":"2023","journal-title":"Clinics"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/svn-2023-002933","article-title":"Optimal duration of dual antiplatelet therapy for minor stroke within 72 hours of symptom onset: a prospective cohort study","volume":"10","author":"Liu","year":"2025","journal-title":"Stroke Vasc Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.25259\/JNRP_278_2024","article-title":"Efficacy and safety of dual-antiplatelet therapy with high-intensity statin versus single-antiplatelet therapy with high-intensity statin in patients with stroke or high-risk mini-stroke of atherosclerotic origin: a cohort study","volume":"16","author":"Suryawanshi","year":"2025","journal-title":"J Neurosci Rural Pract"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1750241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:40:37Z","timestamp":1771911637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1750241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":41,"alternative-id":["10.3389\/fneur.2025.1750241"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1750241","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1750241"}}